

# Pfizer Satellite Symposium at WFH 2024

Monday, April 22<sup>nd</sup>, 18:30 CET,  
Hall 9, Room 1

## New horizons: The value of continued innovation in hemophilia

Therapeutic management of hemophilia has advanced significantly in recent decades via multiple waves of innovation. This session will reflect on recent progress and explore remaining unmet need and next steps for innovation in this space. The discussion will draw from a diverse panel of stakeholders, representing the perspective of hemophilia patients, physicians, health economists and policymakers.

Moderator

**Ms. Grace Hampson**

Associate Director, Office of Health Economics (OHE). United Kingdom

**Dr. Meryem Nimour**

VP, Global Hemophilia Medical Lead, Pfizer. USA

**Mr. Daniel-Aníbal García Diego**

President, Spanish Haemophilia Federation (FEDHEMO). Spain

**Dr. Cedric Hermans**

Head of Haematology Division & Haemophilia Center, Saint-Luc University Hospital, Brussels. Belgium

**Dr. Lou Garrison**

Professor Emeritus, University of Washington, Seattle. USA

**Mr. Malcolm Qualie**

Former Medicines Lead for Specialised Services, NHS. United Kingdom

Timings	Item	Presenter / moderator
5'	Welcome	G. Hampson
25'	Views on the Value of Continued Innovation in Hemophilia	M. Nimour C. Hermans D. García Diego L. Garrison M. Qualie
30'	Panel Discussion and Q&A	All

This symposium is organized and funded by Pfizer, in collaboration with the Office of Health Economics.

This material presented by Pfizer is non-promotional in nature and is presented as information about how Pfizer is working to raise awareness on hemophilia management. Areas that may be discussed include general disease information, patient treatment and management and public health services. In this material, Pfizer does not endorse the use of any treatment as safe/effective for any disease, including those marketed by Pfizer.